[ad_1]
May 9 (Reuters) – Novavax Inc. (NVAX.O) said on Tuesday that a mid-stage study of three of its vaccines, including a combination vaccine targeting COVID-19 and influenza, showed strong immune responses and was found to be safe.
Reporting by Khushi Mandowara in Bengaluru; Editing by Savio D’Souza
Our standards: The Thomson Reuters Trust Principles.
|
Sources 2/ https://www.reuters.com/business/healthcare-pharmaceuticals/novavaxs-covid-flu-vaccine-candidates-show-promise-study-2023-05-09/ The mention sources can contact us to remove/changing this article |
[ad_2]